Jennifer L Uhrlaub
Overview
Explore the profile of Jennifer L Uhrlaub including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1550
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hollister J, Porter C, Sprissler R, Beitel S, Romine J, Uhrlaub J, et al.
PLoS One
. 2024 Dec;
19(12):e0306953.
PMID: 39739951
The extent to which semi-quantitative antibody levels confer protection against SARS-CoV-2 infection in populations with heterogenous immune histories is unclear. Two nested case-control studies were designed within the multisite HEROES/RECOVER...
2.
Porter C, Lyski Z, Uhrlaub J, Ellingson K, Jeddy Z, Gwynn L, et al.
Diseases
. 2024 Aug;
12(8).
PMID: 39195170
Methods: A longitudinal cohort study of children aged ≥ 5 was conducted during August 2021-August 2022, at sites in Arizona, Texas, Utah, and Florida. Children submitted weekly nasal swabs for...
3.
Coplen C, Jergovic M, Terner E, Bradshaw C, Uhrlaub J, Nikolich J
J Virol
. 2024 Apr;
98(5):e0198623.
PMID: 38619272
Importance: The majority of experiments modeling human cytomegalovirus (hCMV) infection in mice have been carried out using intraperitoneal infection in sexually mature adult mice, which stands in contrast to the...
4.
Watanabe M, Davidson L, Smith P, Castellucio P, Jergovic M, Uhrlaub J, et al.
Geroscience
. 2024 Mar;
46(5):4225-4242.
PMID: 38512581
Human cytomegalovirus (hCMV) is a ubiquitous latent persistent herpesvirus infecting 60-90% of the population worldwide. hCMV carriage in immunocompetent people is asymptomatic; thus, hCMV can be considered a component of...
5.
Romine J, Li H, Coughlin M, Jones J, Britton A, Tyner H, et al.
Clin Infect Dis
. 2024 Mar;
79(1):96-107.
PMID: 38466720
Background: There are limited data on whether hybrid immunity differs by count and order of immunity-conferring events (infection with severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] or vaccination against coronavirus...
6.
Jergovic M, Coplen C, Uhrlaub J, Besselsen D, Cheng S, Smithey M, et al.
Nat Commun
. 2024 Jan;
15(1):470.
PMID: 38212327
No abstract available.
7.
Bradshaw C, Georgieva T, Tankersley T, Taylor-Doyle T, Johnson L, Uhrlaub J, et al.
J Immunol
. 2024 Jan;
212(4):523-528.
PMID: 38197714
A popular mouse model of COVID-19, the K18-hACE2 mouse, expresses the SARS-coronavirus entry receptor, human angiotensin-converting enzyme 2 (hACE2) driven by the keratin-18 promoter. SARS-CoV-2-infected K18-hACE2 mice exhibit neuropathology not...
8.
Quirk G, Schoenle M, Peyton K, Uhrlaub J, Lau B, Burgess J, et al.
medRxiv
. 2023 Sep;
PMID: 37745498
Vaccine-induced immunity may impact subsequent responses to drifted epitopes in SARS-CoV-2 variants, but this has been difficult to quantify due to the challenges in recruiting unvaccinated control groups whose first...
9.
Lyski Z, Porter C, Uhrlaub J, Ellingson K, Jeddy Z, Gwynn L, et al.
Open Forum Infect Dis
. 2023 Sep;
10(8):ofad431.
PMID: 37663086
Background: The PROTECT study is a longitudinal cohort study initiated in July 2021 with weekly testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 4 states: Arizona, Florida, exas,...
10.
Herring M, Romine J, Wesley M, Ellingson K, Yoon S, Caban-Martinez A, et al.
Clin Infect Dis
. 2022 Dec;
76(10):1822-1831.
PMID: 36578137
Background: Data on antibody kinetics are limited among individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). From a cohort of healthcare personnel and other frontline workers in...